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Patient Access to New Cancer Drugs in the United States and AustraliaI read with interest the article by Wilson and Cohen published
recently in Value in Health that compared patient access to new
ancer drugs in the United States and Australia over a 10-year
eriod (2000–2009) [1]. The motivation for their study is the ongo-
ng debate in the United States on the greater use of comparative
ffective research (CER) and its effect on patient access to health
are and, in particular, medicines. Australia has extensive experi-
nce in the use of results from CER to inform decisions on patient
ccess to new medicines via the Pharmaceutical Benefits Scheme
PBS), and so the comparison will be of interest to many. Nonethe-
ess, their academic study raises a number of issues.
Wilson and Cohen chose “new cancer drugs” as their study sam-
le. This is surprising, given that the CER movement in the United
tates (and Australia) is not confined to interventions for cancer.
any new drugs for a wide array of diseases/conditions have high
nit prices, not just those for cancer. One could argue that they
hould have compared a wider, more representative sample of new
rugs; this would also have helped to increase their sample size.
They found 34 Food and Drug Administration (FDA)-approved
ew molecular entities and biologics for the treatment of patients
ith cancer in the study period. They did not define cancer; the
nclusion of gemtuzumab ozogamicin, which was first approved
y the FDA for patients with acute myeloid leukemia, suggests the
se of a broad definition that includes hematological cancers and
yndromes (e.g., leukemias and lymphomas).
Their sample also includes the bisphosphonate zoledronic
cid. The FDA first approved zoledronic acid for patients with hy-
ercalcemia of malignancy. The inclusion of zoledronic acid sug-
ests the use of a very liberal definition of cancer because it does
ot have any antineoplastic activity. One could argue why other
ew drugs used by patients with cancer, such as aprepitant, which
as approved by the FDA in 2003 to treat chemotherapy-induced
ausea and vomiting, were not included [2].
Bacillus Calmette-Guérin (or Bacille Calmette-Guérin) (live) is
another interesting inclusion. While Bacillus Calmette-Guérin (or
Bacille Calmette-Guérin) (live) vaccine, as the Connaught and Tice
strains, has been used for many years in the United States and
Australia to treat certain patients with bladder cancer, the Mon-
treal strain (Pacis) is new. Pacis is probably best categorized as a
new formulation/presentation of an existing (biological) drug
rather than a new (biological) drug. The inclusion of Pacis but not
Abraxane (nanoparticle albumin-bound paclitaxel), which was ap-
proved by the FDA in 2005 for the treatment of certain patients
with breast cancer, is puzzling [2].
For unstated reasons, Wilson and Cohen chose to exclude che-
motherapeutic agents and hormonal treatments. If chemothera-
peutic means cytotoxic, then oxaliplatin (platinum compound),
bendamustine (alkylating agent), ixabepilone (cytotoxic antibi-
otic), vorinostat and romidepsin (histone deacetylase inhibitors),
pemetrexed and pralatexate (folate antimetabolites), and nelara-
bine and clofarabine (purine nucleoside metabolic inhibitors)should have been excluded because they are all cytotoxic agents.
Likewise, the hormonal treatments fulvestrant and degarelix
should have been excluded.
The inclusion of everolimus is controversial; while the US FDA
first approved it (as Afinitor) in 2009 for use in certain patients with
renal cell carcinoma, it was first approved by the Therapeutic
Goods Administration (TGA) (as Certican) in Australia in 2005 for
the prophylaxis of organ rejection [3].
Their study sample also has errors of commission; azacitidine
and lenalinomide, which were approved by the FDA for myelodys-
plastic syndrome in 2004 and 2005, respectively, should have been
included [2]. There may be more examples.
The authors claim that 15 of the 34 FDA-approved new molec-
ular entities and biologics had not been approved by the Austra-
lian TGA as of December 31, 2009. One of the 15 is zoledronic acid;
it was approved by the TGA on March 15, 2001. Vorinostat was
approved by the TGA on December 15, 2009 [3].
To enhance their sample size, the authors could have extended
the study period for Australia to include drugs approved by the TGA
after 2009. Pazopanib and ofatumumab were approved by the TGA on
June 22, 2010, and December 15, 2010, respectively [4,5].
The authors speculate as to why the remaining 11 drugs have
been approved only in the United States. One is that the drugs’
sponsors do not have a presence in Australia. Allos Therapeutics,
the sponsor of pralatrexate, and Spectrum Pharmaceuticals, the
sponsor of ibritumomab tiuxetan, do appear not to have any op-
erations outside the United States [6,7]. Cephalon has only re-
cently entered the Australian market by gaining a controlling in-
terest in Arana Therapeutics [8].
The authors used the date of a drug’s first entry into the Aus-
tralian Register of Therapeutic Goods as its date of approval. This
is not always the case. Cetuximab was first registered by the TGA
on February 4, 2005 [9].
New drugs for cancer are approved earlier in the United
States because the FDA has a fast-track, accelerated-approval,
and priority-review process for new drugs to treat serious dis-
eases and fill an unmet medical need [10]. No mention was
made of this. Twenty-two of the 34 drugs were registered under
the accelerated-approval process. Gemtuzumab ozogamicin
has since been withdrawn in the United States because of safety
concerns and a lack of therapeutic benefit [11].
Patient access was studied by examining Medicare beneficia-
ries in the United States and those eligible to access drugs on the
PBS in Australia. The latter covers all Australians, whereas the
former covers only those in the United States who are aged 65
years and older. Wilson and Cohen have not studied the 44% of US
cancer patients aged younger than 65 years who access drugs via
other means. Mason and colleagues [12] have shown that patient
access to new cancer drugs via private insurance is poorer than
with Medicare. One has to question whether those in need of clo-
farabine, which is FDA approved for treatment of pediatric pa-
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blastic leukemia, can do so via Medicare.
The most important metric is probably time from registration
to reimbursement. The time point at which a drug’s reimburse-
ment commences under Medicare Part D is not clear. Imatinib was
first listed on the PBS on December 1, 2001, but only for two of its
three initial TGA-approved indications (accelerated phase and
blast crisis); listing for chronic phase after interferon failure com-
menced on October 21, 2002. Oxaliplatin was first listed on the PBS
on December 1, 2001. Zoledronic acid was first listed on the PBS on
May 1, 2002. The PBS maximum quantity for bevacizumab (either
strength) is one vial [13].
The authors have not explained why they compared prices at a
time point outside of the reimbursement study period. It would have
been more informative if they had cited each drug’s price at reim-
bursement and on December 31, 2009. International price compari-
sons for drugs are problematic for a number of reasons, including
differences in the way prices are reported and the existence of hid-
den discounts and rebates [14]. Average wholesale price, average sell-
ing price, and Medicare Part D prices do not correspond with PBS
prices, which are at the dispensed price (price to patient) level. Three
of the 12 PBS-listed drugs in Table 2 are subject to special pricing
arrangements [13].
Comparing prices at a single time point also fails to account for
currency fluctuations over time. The global price of imatinib was
set in mid-2001 at US$2200 per month when AU$1.00 was worth
approximately US$0.50 [15,16].
The authors may wish to reconsider their results and conclu-
ions in light of the above. CER would be a useful method to deter-
ine whether the 15 [11] drugs that are available in the United
tates but not in Australia are clinically superior to the treatments
hey are likely to replace. It is unclear whether the results and
onclusions from their study are applicable to all new drugs.
In Australia, all who need to access a new cancer drug are invari-
bly able to do so via the PBS with a modest patient co-payment.
ccess can be rapid in situations where there is no time to lose (e.g.,
matinib), even in the absence of randomized controlled trial evi-
ence. In the United States, access is highly variable depending on
ne’s age and/or income with higher patient co-payments. High pa-
ient co-payments associated with the Medicare Part D “donut hole”
re reducing access [17]. Which country has the better access to new
ancer drugs? Until there is an established evaluation framework,
he jury will remain out. While the United States might be ahead in
erms of breadth (i.e., more drugs) and timeliness, Australia seems to
are better on equity and sustainability [18].
Michael Wonder, BSc (Hons), BPharm
Consultant Health Economist, New South Wales, Australia
1098-3015/$36.00 – see front matter
Copyright © 2012, International Society for
Pharmacoeconomics and Outcomes Research (ISPOR).
Published by Elsevier Inc.doi:10.1016/j.jval.2011.10.012
data sample as a cancer drug when it is in fact not an antineoplas-R E F E R E N C E S
[1] Wilson A, Cohen J. Patient access to new cancer drugs in the United
States and Australia. Value Health 2011;14:944–52.
[2] US Department of Health and Human Services, US Food and Drug
Administration. Drugs @FDA: FDA approved drug products. Available
from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
[Accessed September 5, 2011].
[3] Therapeutic Goods Administration. eBS Australian Register of
Therapeutic Goods Medicines. Available from: https://www.ebs.tga.
gov.au/ebs/ANZTPAR/PublicWeb.nsf/cuMedicines?OpenView.
[Accessed September 5, 2011].
[4] Therapeutics Goods Administration. Australian public assessment
report for prescription medicines: Votrient (pazopanib). Available
from: http://www.tga.gov.au/pdf/auspar/auspar-votrient.pdf.
[Accessed September 3, 2011].
[5] Therapeutics Goods Administration. Australian public assessment
report for prescription medicines: Arzerra (otafumumab). Available
from: http://www.tga.gov.au/pdf/auspar/auspar-arzerra.pdf. [Accessed
September 3, 2011].
[6] Allos Therapeutics. Company overview. Available from: http://www.
allos.com/company-overview-mainxxzxqma318.cfm. [Accessed
September 3, 2011].
[7] Spectrum Pharmaceuticals. About Spectrum Pharmaceuticals Inc.
Available from: http://www.sppirx.com/about_Spectrum.html.
[Accessed September 6, 2011].
[8] Cephalon. Cephalon acquires controlling interest in Arana
Therapeutics. News Release May 20, 2009. Available from: http://
investors.cephalon.com/phoenix.zhtml?c81709&pirol-newsArticle&
ID1290449&highlight. [Accessed September 6, 2011].
[9] Australian Government, Department of Health and Ageing,
Pharmaceutical Benefits Scheme, Public Summary Documents. Public
summary document for cetuximab (November 2008). Available from:
http://www.health.gov.au/internet/main/publishing.nsf/Content/
pbac-psd-cetuximab-nov08. [Accessed September 3, 2011].
10] US Department of Health and Human Services, US Food and Drug
Administration. Fast track, accelerated approval and priority review.
Available from: http://www.fda.gov/forconsumers/byaudience/for
patientadvocates/speedingaccesstoimportantnewtherapies/
ucm128291.htm#accelerated. [Accessed September 5, 2011].
11] US Department of Health and Human Services, US Food and Drug
Administration, News and Events. FDA: Pfizer voluntarily withdraws
cancer treatment Mylotarg from U.S. Market. FDA News Release. June
21, 2010. Available from: http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm216448.htm. [Accessed September 3, 2011].
[12] Mason A, Drummond M, Ramsey S, et al. Comparison of anticancer
drug coverage decisions in the United States and United Kingdom:
does the evidence support the rhetoric? J Clin Oncol 2010;28(20):
3234–8.
[13] Australian Government, Department of Health and Ageing.
Pharmaceutical Benefits Scheme. Available from: http://www.pbs.gov.
au/pbs/home. [Accessed September 5, 2011].
[14] Danzon PM, Kim JD. International price comparisons for
pharmaceuticals: measurement and policy issues. Pharmacoeconomics
1998;14(Suppl. 1):115–28.
[15] Vasella D. Magic Cancer Bullet: How a Tiny Orange Pill Is Rewriting
Medical History. New York: Harper Collins, 2003.
[16] xe.com. Current and historical rate tables. Available from: http://
www.xe.com/ict/. [Accessed September 6, 2011].
[17] Polinski JM, Shrank WH, Huskamp HA, et al. Changes in drug
utilization during a gap in insurance coverage: an examination of the
Medicare Part D coverage gap. PLoS Med 2011;8:e1001075.[18] Anonymous. Bleak news on health insurance [editorial]. New York
Times. September 14, 2011:A34Patient Access to New Cancer Drugs in the United States and
Australia—Reply to Letter to the Editor by Dr. WonderTo the Editor – Dr. Wonder is correct to point out inconsistencies in
our article, among which is our inclusion of zoledronic acid in thetic. Also, we should have included lenalidomide in our sample
because it was approved by the Food and Drug Administration in
2005 for a cancer indication. Furthermore, we failed to mention
